Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs

Oncology (Williston Park). 2013 Sep;27(9):865-6, 871.
No abstract available

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / economics*
  • Cost Savings
  • Cost-Benefit Analysis
  • Drug Costs*
  • Health Care Reform / economics
  • Health Care Reform / legislation & jurisprudence
  • Health Policy / economics*
  • Health Policy / legislation & jurisprudence
  • Health Services Accessibility / economics*
  • Health Services Accessibility / legislation & jurisprudence
  • Healthcare Disparities / economics*
  • Healthcare Disparities / legislation & jurisprudence
  • Humans
  • Insurance Coverage / economics
  • Insurance Coverage / legislation & jurisprudence
  • Insurance, Health / economics
  • Insurance, Health / legislation & jurisprudence
  • Patient Protection and Affordable Care Act / economics
  • Patient Protection and Affordable Care Act / legislation & jurisprudence
  • Treatment Outcome
  • United States

Substances

  • Antineoplastic Agents